Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.47 |
| ▸ | CTSL | P07711 | 5/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478908 | 1.00 | CTSK (0.47) | CTSKCTSLCTSBCTSSCASP3 | |
| SCHEMBL4861261 | 1.00 | CTSK (0.47) | CTSKCTSLCTSBCTSSCASP3 | |
| SCHEMBL4869543 | 1.00 | CTSK (0.47) | CTSKCTSLCTSBCTSSCASP3 | |
| SCHEMBL30975235 | 0.91 | CTSK (0.46) | CTSKCTSLCTSBCTSSCASP3 | |
| SCHEMBL30975232 | 0.91 | CTSK (0.46) | CTSKCTSLCTSBCTSSCASP3 | |
| SCHEMBL3165723 | 0.88 | CTSK (0.49) | CTSKCTSLCTSBCTSSCASP3 | |
| SCHEMBL4483343 | 0.88 | CTSK (0.49) | CTSKCTSLCTSBCTSSCASP3 | |
| SCHEMBL4492874 | 0.88 | CTSK (0.49) | CTSKCTSLCTSBCTSSCASP3 | |
| SCHEMBL6230798 | 0.88 | CTSK (0.49) | CTSKCTSLCTSBCTSSCASP3 | |
| SCHEMBL4483853 | 0.88 | CTSK (0.49) | CTSKCTSLCTSBCTSSCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429587-B2 | Pyrrolidine derivatives as factor Xa inhibitors | GLAXO GROUP LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7282497-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2007-10-16 | — | — | US | disclosed |
| US-20070155745-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | CHAN CHUEN | 2007-07-05 | — | — | US | disclosed |
| US-20060160886-A1 | Synergistic mixtures of 6-Chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide and 4-chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide; improved oral bioavailability and pharmacokinetics | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155745-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | TFPI, F2, SERPINC1 | CTSK 380/4885CTSL 267/4885CTSB 291/4885 |
| US-20060160886-A1 | Synergistic mixtures of 6-Chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide and 4-chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide; improved oral bioavailability and pharmacokinetics | SULT1E1, SULT1A1, SULT2A1 | CTSK 1104/4885CTSL 423/4885CTSB 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.